# Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

> **NCT00502060** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 65 (estimated)

## Conditions studied

- Advanced Tumor

## Interventions

- **DRUG:** AZD2171
- **DRUG:** ZD1839

## Key facts

- **NCT ID:** NCT00502060
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-06
- **Final completion:** 2006-06
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2009-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00502060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00502060, "Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT00502060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*